Evidence map›Paper›PMID 40217526›Full record

ArticleBioData mining2025

Towards precision oncology: a multi-level cancer classification system integrating liquid biopsy and machine learning.

Amr Eledkawy, Taher Hamza, Sara El-Metwally

Abstract read
In one paragraph

Article in BioData mining, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amr EledkawyDepartment of Computer Science, Faculty of Computers and Information, Mansoura University, P.O. Box: 35516, Mansoura, Egypt.
Taher HamzaDepartment of Computer Science, Faculty of Computers and Information, Mansoura University, P.O. Box: 35516, Mansoura, Egypt.
Sara El-MetwallyDepartment of Computer Science, Faculty of Computers and Information, Mansoura University, P.O. Box: 35516, Mansoura, Egypt. sarah_almetwally4@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMillions of people die from cancer every year. Early cancer detection is crucial for ensuring higher survival rates, as it provides an opportunity for timely medical interventions. This paper proposes a multi-level cancer classification system that uses plasma cfDNA/ctDNA mutations and protein biomarkers to identify seven distinct cancer types: colorectal, breast, upper gastrointestinal, lung, pancreas, ovarian, and liver.

resultsThe proposed system employs a multi-stage binary classification framework where each stage is customized for a specific cancer type. A majority vote feature selection process is employed by combining six feature selectors: Information Value, Chi-Square, Random Forest Feature Importance, Extra Tree Feature Importance, Recursive Feature Elimination, and L1 Regularization. Following the feature selection process, classifiers-including eXtreme Gradient Boosting, Random Forest, Extra Tree, and Quadratic Discriminant Analysis-are customized for each cancer type individually or in an ensemble soft voting setup to optimize predictive accuracy. The proposed system outperformed previously published results, achieving an AUC of 98.2% and an accuracy of 96.21%. To ensure reproducibility of the results, the trained models and the dataset used in this study are made publicly available via the GitHub repository ( https://github.com/SaraEl-Metwally/Towards-Precision-Oncology ).

conclusionThe identified biomarkers enhance the interpretability of the diagnosis, facilitating more informed decision-making. The system's performance underscores its effectiveness in tissue localization, contributing to improved patient outcomes through timely medical interventions.

Indexed as

CfDNA/ctDNAEnsemble learningLiquid biopsyMajority vote feature selectionMulti-cancer classificationProtein biomarkers

Identifiers

PMID40217526
PMCPMC11987386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.